{"date":"2026-09-18","count":15,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6986-2026-09-18-1905-gi3647","company_id":"6986","company":"和迅","market":"上櫃","industry":"生技醫療","date":"2026-09-18","time":"19:05:14","subject":"公告本公司董事會決議買回庫藏股事宜","clause":"第35款","fact_date":"2026-09-18","cite_as":"公開資訊觀測站重大訊息：和迅（6986），2026-09-18 19:05，「公告本公司董事會決議買回庫藏股事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7871-2026-09-18-1753-1bcv4sg","company_id":"7871","company":"安立璽榮-KY","market":"興櫃","industry":"生技醫療","date":"2026-09-18","time":"17:53:58","subject":"公告本公司取得會計師內部控制制度專案審查確信報告","clause":"第25款","fact_date":"2026-09-18","cite_as":"公開資訊觀測站重大訊息：安立璽榮-KY（7871），2026-09-18 17:53，「公告本公司取得會計師內部控制制度專案審查確信報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7871-2026-09-18-1753-7qwiow","company_id":"7871","company":"安立璽榮-KY","market":"興櫃","industry":"生技醫療","date":"2026-09-18","time":"17:53:01","subject":"代重要子公司安立璽榮生醫股份有限公司公告，用於治療阿茲海默症(Alzheimer’s Disease)之新藥EI-1071已向TFDA提出食物影響之第一期臨床試驗申請","clause":"第8款","fact_date":"2026-07-28","cite_as":"公開資訊觀測站重大訊息：安立璽榮-KY（7871），2026-09-18 17:53，「代重要子公司安立璽榮生醫股份有限公司公告，用於治療阿茲海默症(Alzheimer’s Disease)之新藥EI-107」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7871-2026-09-18-1752-7qwiow","company_id":"7871","company":"安立璽榮-KY","market":"興櫃","industry":"生技醫療","date":"2026-09-18","time":"17:52:27","subject":"代重要子公司安立璽榮生醫股份有限公司公告，用於治療阿茲海默症(Alzheimer’s Disease)之新藥EI-1071二期人體臨床試驗計畫書修正案經TFDA審核通過","clause":"第8款","fact_date":"2026-09-18","cite_as":"公開資訊觀測站重大訊息：安立璽榮-KY（7871），2026-09-18 17:52，「代重要子公司安立璽榮生醫股份有限公司公告，用於治療阿茲海默症(Alzheimer’s Disease)之新藥EI-107」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6919-2026-09-18-1710-ygcm51","company_id":"6919","company":"康霈*","market":"上市","industry":"生技醫療","date":"2026-09-18","time":"17:10:13","subject":"本公司新藥CBL-514注射劑之樞紐三期臨床試驗CBL-0302向加拿大HC申請之試驗變更案已核准執行。","clause":"第10款","fact_date":"2026-09-18","cite_as":"公開資訊觀測站重大訊息：康霈*（6919），2026-09-18 17:10，「本公司新藥CBL-514注射劑之樞紐三期臨床試驗CBL-0302向加拿大HC申請之試驗變更案已核准執行。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4147-2026-09-18-1646-a07xeb","company_id":"4147","company":"中裕","market":"上櫃","industry":"生技醫療","date":"2026-09-18","time":"16:46:09","subject":"本公司行銷夥伴AcedrA BioPharmaceuticals向沙烏地阿拉伯食品藥品管理局(SFDA)申請愛滋病新藥Trogarzo生物製劑註冊審查進展說明及後續因應措施","clause":"第10款","fact_date":"2026-09-18","cite_as":"公開資訊觀測站重大訊息：中裕（4147），2026-09-18 16:46，「本公司行銷夥伴AcedrA BioPharmaceuticals向沙烏地阿拉伯食品藥品管理局(SFDA)申請愛滋病新藥T」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6875-2026-09-18-1628-1286rxu","company_id":"6875","company":"國邑*","market":"上櫃","industry":"生技醫療","date":"2026-09-18","time":"16:28:17","subject":"本公司吸入新藥L608(微脂體-伊洛前列素)，通過美國食品藥物管理局(FDA)人體二期臨床試驗審查(IND)","clause":"第10款","fact_date":"2026-09-18","cite_as":"公開資訊觀測站重大訊息：國邑*（6875），2026-09-18 16:28，「本公司吸入新藥L608(微脂體-伊洛前列素)，通過美國食品藥物管理局(FDA)人體二期臨床試驗審查(IND)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4905-2026-09-18-1621-hntsjt","company_id":"4905","company":"台聯電","market":"上櫃","industry":"生技醫療","date":"2026-09-18","time":"16:21:38","subject":"代重要子公司欣德芮(股)公司公告股東臨時會重要決議事項","clause":"第18款","fact_date":"2026-09-18","cite_as":"公開資訊觀測站重大訊息：台聯電（4905），2026-09-18 16:21，「代重要子公司欣德芮(股)公司公告股東臨時會重要決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7799-2026-09-18-1554-tqzpae","company_id":"7799","company":"禾榮科","market":"上市","industry":"生技醫療","date":"2026-09-18","time":"15:54:26","subject":"本公司有價證券於集中交易市場達公布注意交易資訊標準，故公布相關財務業務等重大訊息，以利投資人區別瞭解","clause":"第51款","fact_date":"2026-09-18","cite_as":"公開資訊觀測站重大訊息：禾榮科（7799），2026-09-18 15:54，「本公司有價證券於集中交易市場達公布注意交易資訊標準，故公布相關財務業務等重大訊息，以利投資人區別瞭解」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6748-2026-09-18-1534-t2b78m","company_id":"6748","company":"亞果生醫","market":"興櫃","industry":"生技醫療","date":"2026-09-18","time":"15:34:59","subject":"公告本公司亞比斯可拉 骨填料ABCcolla Bone Graft取得印度醫療器材上市許可證","clause":"第44款","fact_date":"2026-09-18","cite_as":"公開資訊觀測站重大訊息：亞果生醫（6748），2026-09-18 15:34，「公告本公司亞比斯可拉 骨填料ABCcolla Bone Graft取得印度醫療器材上市許可證」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6499-2026-09-18-1513-1xu2zu0","company_id":"6499","company":"益安","market":"上櫃","industry":"生技醫療","date":"2026-09-18","time":"15:13:58","subject":"本公司董事會通過簽署與Terumo之和解暨終止協議","clause":"第53款","fact_date":"2026-09-18","cite_as":"公開資訊觀測站重大訊息：益安（6499），2026-09-18 15:13，「本公司董事會通過簽署與Terumo之和解暨終止協議」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6876-2026-09-18-1444-4e4bwm","company_id":"6876","company":"朗齊生醫*","market":"興櫃","industry":"生技醫療","date":"2026-09-18","time":"14:44:12","subject":"更正公告本公司LXP105應用於第二期三陰性乳癌(Triple-NegativeBreast Cancer, TNBC）新輔助治療的探索性臨床研究，獲國際腫瘤學期刊《Frontiers in Oncology》接受並準備發表。","clause":"第44款","fact_date":"2026-09-17","cite_as":"公開資訊觀測站重大訊息：朗齊生醫*（6876），2026-09-18 14:44，「更正公告本公司LXP105應用於第二期三陰性乳癌(Triple-NegativeBreast Cancer, TNBC）」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3705-2026-09-18-1437-16sohr8","company_id":"3705","company":"永信","market":"上市","industry":"生技醫療","date":"2026-09-18","time":"14:37:42","subject":"本公司受邀參加元大證券舉辦之線上法人說明會","clause":"第12款","fact_date":"2026-09-21","cite_as":"公開資訊觀測站重大訊息：永信（3705），2026-09-18 14:37，「本公司受邀參加元大證券舉辦之線上法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6876-2026-09-18-1412-mkduar","company_id":"6876","company":"朗齊生醫*","market":"興櫃","industry":"生技醫療","date":"2026-09-18","time":"14:12:47","subject":"公告本公司LXP105應用於第二期三陰性乳癌(Triple-NegativeBreast Cancer, TNBC）新輔助治療的探索性臨床研究，獲國際腫瘤學期刊《Frontiers in Oncology》接受並準備發表。","clause":"第44款","fact_date":"2026-06-17","cite_as":"公開資訊觀測站重大訊息：朗齊生醫*（6876），2026-09-18 14:12，「公告本公司LXP105應用於第二期三陰性乳癌(Triple-NegativeBreast Cancer, TNBC）新輔」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6446-2026-09-18-0536-kccqqt","company_id":"6446","company":"藥華藥","market":"上市","industry":"生技醫療","date":"2026-09-18","time":"05:36:43","subject":"本公司P1101用於早前期原發性骨髓纖維化或低或中度風險1級的明顯原發性骨髓纖維化之第三期臨床試驗獲數據安全監督委員會（DSMB）正面回應，建議持續進行","clause":"第10款","fact_date":"2026-09-17","cite_as":"公開資訊觀測站重大訊息：藥華藥（6446），2026-09-18 05:36，「本公司P1101用於早前期原發性骨髓纖維化或低或中度風險1級的明顯原發性骨髓纖維化之第三期臨床試驗獲數據安全監督委員會（」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}